Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.02 USD
Change Today -0.10 / -4.72%
Volume 364.4K
ARQL On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 04/27/15 All times are local (Market data is delayed by at least 15 minutes).

arqule inc (ARQL) Snapshot

Open
$2.11
Previous Close
$2.12
Day High
$2.12
Day Low
$1.91
52 Week High
03/9/15 - $2.50
52 Week Low
10/15/14 - $1.04
Market Cap
126.9M
Average Volume 10 Days
313.4K
EPS TTM
$-0.36
Shares Outstanding
62.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ARQULE INC (ARQL)

arqule inc (ARQL) Related Businessweek News

No Related Businessweek News Found

arqule inc (ARQL) Details

ArQule, Inc., a clinical-stage biotechnology company, researches and develops therapeutics for the treatment of cancer and rare diseases. Its lead product candidate is tivantinib, a small molecule inhibitor of the c-Met receptor tyrosine kinase and its biological pathway, which is in Phase III clinical trial for the treatment of liver cancer and non-small cell lung cancer; Phase II clinical trial for the treatment of mesothelioma and kidney cancer; and Phase I clinical trial for the treatment of pediatric tumors, as well as has completed Phase II clinical trial for the treatment of colorectal cancer. The company’s early clinical-stage products in Phase Ib clinical trials include ARQ 092, an inhibitor of the AKT serine/threonine kinase; ARQ 087, a multi-kinase inhibitor of the fibroblast growth factor receptor (FGFR) family for patients with cholangiocarcinoma and adrenocortical tumors, as well as with FGFR translocations, amplification, and mutations; and ARQ 761, an intravenously administered analogue of Beta-lapachone, which is used as a promoter of NQ01-mediated programmed cancer cell necrosis. Its pre-clinical development program includes ARQ 751, a next-generation inhibitor of AKT. ArQule, Inc. has partnership agreement with Daiichi Sankyo Co., Ltd. to conduct research, clinical trials, and the commercialization of tivantinib for human cancer indications in the United States, Europe, South America, and internationally; and Kyowa Hakko Kirin Co., Ltd. to develop and commercialize tivantinib in Japan and parts of Asia. The company has collaboration agreement with the National Human Genome Research Institute of the NIH for a clinical trial investigating on ARQ 092, which is used for the treatment of Proteus syndrome. ArQule, Inc. was founded in 1993 and is headquartered in Woburn, Massachusetts.

40 Employees
Last Reported Date: 03/4/15
Founded in 1993

arqule inc (ARQL) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $489.3K
President, Principal Financial Officer, Chief...
Total Annual Compensation: $413.9K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $394.6K
Compensation as of Fiscal Year 2014.

arqule inc (ARQL) Key Developments

ArQule Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-14-2015 03:00 PM

ArQule Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-14-2015 03:00 PM. Venue: Westin Grand Central Hotel, New York, New York, United States.

ArQule Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Earnings Guidance for the Full Year 2015

ArQule Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, research and development revenue was $3,015,000 against $2,275,000 a year ago. Loss from operations was $4,111,000 against $6,170,000 a year ago. Net loss was $3,512,000 or $0.06 per basic and diluted share against $5,956,000 or $0.10 per basic and diluted share a year ago. The $4.6 million revenue decrease in 2014 is primarily due to revenue decreases of $2.2 million from its Daiichi Sankyo tivantinib program due to a change in the estimated development period; $1.2 million from its Daiichi Sankyo 092 agreement that ended in June 2013; and $1.7 million of other revenue from a onetime research project that was completed in 2013. These decreases were partially offset by lower contra-revenue of $0.5 million. For the full year, research and development revenue was $11,254,000 against $15,914,000 a year ago. Loss from operations was $24,270,000 against $25,127,000 a year ago. Net loss was $23,391,000 or $0.37 per basic and diluted share against $24,600,000 or $0.39 per basic and diluted share a year ago. For the full year of 2015, the company expects net use of cash to range between $26 million and $29 million. Revenues are expected to range between $8 million and $10 million. Net loss is expected to range between $18 million and $21 million, and net loss per share to range between $0.29 and $0.33 for the year. The company expects to end 2015 with between $32 million and $35 million in cash and marketable securities.

ArQule Inc. to Report Q4, 2014 Results on Mar 04, 2015

ArQule Inc. announced that they will report Q4, 2014 results at 9:00 AM, US Eastern Standard Time on Mar 04, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARQL:US $2.02 USD -0.10

ARQL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AVEO Pharmaceuticals Inc $1.82 USD -0.10
CrystalGenomics Inc 12,500 KRW -200.00
Curis Inc $2.88 USD -0.08
Cytokinetics Inc $6.83 USD -0.42
Rigel Pharmaceuticals Inc $4.69 USD -0.185
View Industry Companies
 

Industry Analysis

ARQL

Industry Average

Valuation ARQL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 11.8x
Price/Book 3.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARQULE INC, please visit www.arqule.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.